Compare Gilead Sciences, Inc. (GILD) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Invesco S&P 500 High Div Low Volatility ETF trades at $48.82 (market cap $3.14B). The key difference: Gilead Sciences, Inc. is far larger — about 58.1× Invesco S&P 500 High Div Low Volatility ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Invesco S&P 500 High Div Low Volatility ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Invesco S&P 500 High Div Low Volatility ETF for 125 Days on average.
| GILD | SPHD | |
|---|---|---|
Market Cap | $182.40B | $3.14B |
Volume | 4,469,821 | 1,461,349 |
Sector | Health | — |
52-Week High | $155.80 | $53.55 |
52-Week Low | $117.18 | $46.96 |
Typical Hold Time | 111 Days | 125 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, showing modest daily gains of 0.17% with strong technical support at $145. The company demonstrates robust fundamentals with Q2 2026 earnings beating expectations despite a net loss, while maintaining a high gross margin of 79.59%. Recent developments include expanded HIV prevention drug access across Latin America through a PAHO partnership, positioning the company for growth in key therapeutic areas.
GILD presents a mixed outlook with strong analyst support (65.5% buy ratings) and a $151.57 price target offering 3% upside, but faces headwinds from negative net income margins and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, though investors should monitor the company's ability to translate top-line strength into sustainable profitability amid competitive pressures.
SPHD trades at $48.81, up 1.29% today, but faces bearish technical signals with 17 sell indicators versus 4 buy signals. The ETF's monthly dividend structure provides consistent income, though recent analysis highlights underperformance compared to peers like SCHD over the past decade. Current technical positioning shows oversold conditions with RSI readings below 15, suggesting potential for near-term bounce despite the dominant bearish trend.
The outlook remains cautious as SPHD's high-dividend, low-volatility strategy faces challenges in maintaining total returns. Key risks include yield trap exposure and weaker drawdown recovery compared to quality-focused alternatives. For income-focused investors, the monthly dividend provides utility, but long-term capital appreciation appears limited based on historical performance trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
